

Commercial Medicines Unit

NHS England

2nd Floor

Rutland House

Runcorn

Cheshire

WA7 2ES

**All messages regarding the  
Offer documentation should**

**be sent via the Atamis Website:**

health.atamis.co.uk

**Thursday 2nd November 2023**

**Invitation to offer for NHS National Framework for Natalizumab - February 2024**

**Offer reference number: CM/PHR/23/5701**

**Period of framework: 1 February 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.**

NHS England (‘Authority’) invites offers for the above-mentioned goods and/or services as defined in Document No. 03 Framework Agreement and Terms and Conditions. Offers shall be made subject to the terms of:

Document No.01 This covering letter

Document No.02 Terms of offer

Document No.03 Framework Agreement and Terms and Conditions

Document No.04a Quality Assurance Process

Document No.04b Assessment Criteria, Stability Protocol and Additional Specification Requirements

Document No.05 Selectt offer schedule instructions

Document No.05a Selectt Offer schedule – CM\_PHR\_23\_5701

Document No.05b Tender Product listing and usage – CM\_PHR\_23\_5701

Document No.05c Volume discounts or additional products offer schedule

Document No.06 Form of offer

Document No.07a Quality control technical sheet

Document No.07b Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines v6 (Issued October 2023)

Document No. 08 Confidential information schedule

Document No. 09 Tender Design and Instructions on completing the offer schedule

Document No. 10 Participating Authorities

all of which constitute this Invitation to offer.

If any of the documents constituting the Invitation to offer is missing please contact the undersigned immediately via the Atamis messaging portal.

The Authority does not bind itself to accept the lowest offer or any offer at all and reserves the right to accept an offer either in whole or in part, each item being for this purpose treated as offered separately. The Authority reserves the right to conclude a framework agreement for the supply of the goods and/or services with more than one Offeror.

I would like to draw your attention to the following important points when completing and submitting your offer:

1. All offers must be written in English.

2. All offers must be submitted subject to and in accordance with the documentation comprising the Invitation to offer. Save where the Offerors are instructed to provide information, the documentation comprising the Invitation to offer must not be amended in any way.

3. All offers must be loaded onto the Commercial Medicines Unit’s eTendering portal health.atamis.co.uk

4. Offers must be open for 90 days.

5. Offers must be fully completed and available on the designated website no later than **13:00** on **Monday 4th December 2023.**

I must also draw your attention to the enclosed Form of offer where all the requirements for completing and submitting an offer can be found. Failure to comply with these instructions may result in your offer being rejected.

I hope that the above instructions are clear but please contact the undersigned via the Atamis messaging portal if there is anything you wish to clarify.

Yours faithfully

A group of signature on a white background

Description automatically generated

Katie Noonan

Sourcing Specialist

Branded, Biosimilars and IV Fluids Procurement Support